科尔迪塞通过降低MYC调节来改善质母细胞细胞对temozolomide的敏感性
Shi-Xing Zheng1, Jing Chen2, Bing-Bo Zhuang1
1Department of Neurosurgery, Fujian Medical University Union Hospital, 29# Xinquan Road, Fuzhou, 350001, Fujian, China.
Journal of cancer research and clinical oncology
|September 11, 2023
概括
这项研究表明,cordycepin和temozolomide的组合有效地抑制了质母细胞瘤的生长和迁移. 这种组合针对关键的癌症通路,为这种攻击性脑瘤提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 质母细胞瘤是一种具有侵略性的脑瘤,治疗选择有限,预后不佳.
- 目前用于质母细胞瘤的治疗方法经常面临有效性和耐药性的挑战.
研究的目的:
- 为了研究cordycepin与temozolomide结合对质母细胞瘤的协同效应.
- 使用网络药理学和生物验证,阐明这种药物组合抗癌活性背后的分子机制.
主要方法:
- 网络药理学被用来识别潜在的药物点和途径.
- 使用LN-229质母细胞细胞进行了体外研究,以评估细胞生长,增殖,迁移和入侵.
- 分析了参与癌症途径的关键分子的基因和蛋白质表达水平.
主要成果:
- 康迪塞宾和泰莫索洛米德的组合显著抑制了质母细胞瘤细胞的生长,增殖,迁移和入侵.
- 该药物组合通过调节E-cadherin,N-cadherin,Zeb1和Twist1的表达方式来抑制表皮质-介质细胞过渡 (EMT).
- 网络药理学确定了36个常见的标,并突出了诸如"癌症中的微RNA"和"PI3K-AKT信号通路"等途径;关键的基因表达变化包括MYC的下调和PDCD4的上调.
结论:
- 科尔迪塞宾和泰莫索洛米德的组合显示出显著的抗质母细胞瘤活性.
- 该机制涉及通过特定癌症相关途径降低MYC的调节,随后影响细胞增殖,迁移和细胞亡.
- 这种组合疗法为质母细胞瘤治疗提供了一个有前途的策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K


